Expansion of Quotient Sciences' UK drug development and manufacturing facilities
Quotient Sciences’ Nottingham and Reading facilities have announced the completion of their facility expansions, providing further capabilities to support their flagship program Translational Pharmaceutics®.
Drug development and manufacturing accelerator Quotient Sciences has completed their expansions and investments in their Nottingham and Reading (both UK) facilities for the delivery and support of fully integrated drug development programs through Translational Pharmaceutics®, Quotient Sciences’ flagship platform.
As a platform, Translational Pharmaceutics integrates programs for drug substance, drug product, and clinical testing activities under a single outsourcing provider, with the goal of accelerating development timelines while reducing costs. The platform, which utilises rapid “make-test” cycles wherein drug products run through the clinical study manufacturing, release, and dosing process in days, was developed with consultation from the MHRA and US FDA. Quotient Sciences’ investments in their expanded laboratory and clinical pharmacology spaces will increase their capacity to conduct programs with Translational Pharmaceutics.
Quotient Sciences Nottingham facility boasts an MHRA-inspected clinical pharmacology facility spanning 17,000 square feet, with processing labs, a dispensary, and controlled storage. The facility sits alongside their existing facilities specialising in formulation development, manufacturing, and clinical operations. Their Reading site has completed a GBP £1.5 million expansion for its early development and manufacturing facility.
Mark Egerton, CEO of Quotient Sciences, commented: “Quotient Science’s mission is to help bring new medicines to patients faster by breaking own traditional industry silos... Our Unique Translational Pharmaceutics platform was launched over 15 years ago and has accelerated the development of close to 1,000 molecules for our customers. These expansions are consistent with our overall growth strategy and in direct response to feedback from our customers and the increasing demand for our services.”
Source: Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics®
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance